Active substance
Results for the substance natalizumab
3 results
About this active substance
Natalizumab is a monoclonal antibody used in the treatment of relapsing multiple sclerosis and active Crohn's disease. It works by blocking adhesion molecules on the surface of leukocytes, preventing their migration into inflamed tissues.
The medication is administered via intravenous infusion, usually once every four weeks. It is important for patients to be monitored for potential adverse reactions, such as infections or allergic responses.
Natalizumab is contraindicated in patients with active infections or a history of progressive multifocal leukoencephalopathy. Its use during pregnancy should also be carefully evaluated.
This medication is an important option for patients with multiple sclerosis or Crohn's disease, helping to reduce relapses and improve quality of life.
The medication is administered via intravenous infusion, usually once every four weeks. It is important for patients to be monitored for potential adverse reactions, such as infections or allergic responses.
Natalizumab is contraindicated in patients with active infections or a history of progressive multifocal leukoencephalopathy. Its use during pregnancy should also be carefully evaluated.
This medication is an important option for patients with multiple sclerosis or Crohn's disease, helping to reduce relapses and improve quality of life.